TAK Stock Overview
Engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Takeda Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥13.61 |
| 52 Week High | JP¥15.08 |
| 52 Week Low | JP¥12.58 |
| Beta | 0.46 |
| 1 Month Change | 1.95% |
| 3 Month Change | -1.23% |
| 1 Year Change | -2.79% |
| 3 Year Change | -9.39% |
| 5 Year Change | -30.77% |
| Change since IPO | -35.95% |
Recent News & Updates
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Jan 31Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors
Dec 07Recent updates
Strong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be Undervalued
Jan 31Takeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US Investors
Dec 07Takeda Pharmaceuticals: An Interesting Option For Income Investors
Oct 07Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk
Jun 06Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits
Mar 03Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play
Oct 24Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)
Aug 31Takeda: Upside Case Strengthening, Looking To 15x Earnings
Jun 21Shareholder Returns
| TAK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.7% | 1.3% | 0.6% |
| 1Y | -2.8% | 1.2% | 22.4% |
Return vs Industry: TAK underperformed the US Pharmaceuticals industry which returned 1.2% over the past year.
Return vs Market: TAK underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| TAK volatility | |
|---|---|
| TAK Average Weekly Movement | 2.4% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TAK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TAK's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1781 | 49,281 | Christophe Weber | www.takeda.com |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands.
Takeda Pharmaceutical Company Limited Fundamentals Summary
| TAK fundamental statistics | |
|---|---|
| Market cap | US$43.45b |
| Earnings (TTM) | US$1.37b |
| Revenue (TTM) | US$30.12b |
31.8x
P/E Ratio1.4x
P/S RatioIs TAK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TAK income statement (TTM) | |
|---|---|
| Revenue | JP¥4.58t |
| Cost of Revenue | JP¥1.59t |
| Gross Profit | JP¥2.99t |
| Other Expenses | JP¥2.79t |
| Earnings | JP¥208.07b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 131.26 |
| Gross Margin | 65.38% |
| Net Profit Margin | 4.54% |
| Debt/Equity Ratio | 65.2% |
How did TAK perform over the long term?
See historical performance and comparisonDividends
4.7%
Current Dividend Yield145%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 22:34 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Takeda Pharmaceutical Company Limited is covered by 38 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hazim Bahari | CFRA Equity Research |